Abstract
Dermatologists face diagnostic and therapeutic difficulties when psoriasis coexists with human immunodeficiency virus (HIV) infection. This article will review some of the aspects of this coexistence from the epidemiologic, pathogenic, histopathologic, clinical, and prognostic point of view. The main skin diseases that should be included in the differential diagnosis are described. Also analyzed are the different therapeutic options in these patients according to the degree of immunodeficiency. Possibilities include antiretroviral treatment, topical treatment, retinoids, and classic immunosuppressants. The review will also cover current literature on the use of new biologic therapies in patients with HIV infection. Finally, we will discuss the risk of drug interactions during psoriasis treatment in these patients, who receive multiple pharmacologic therapies.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS-Related Opportunistic Infections / prevention & control
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Biological Therapy
-
Combined Modality Therapy
-
Comorbidity
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / pharmacokinetics
-
Dermatologic Agents / therapeutic use
-
Diagnosis, Differential
-
Drug Interactions
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology
-
HIV Infections / immunology
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / pharmacokinetics
-
Immunosuppressive Agents / therapeutic use
-
PUVA Therapy
-
Polypharmacy
-
Prognosis
-
Psoriasis / complications*
-
Psoriasis / diagnosis
-
Psoriasis / drug therapy
-
Psoriasis / epidemiology
-
Psoriasis / immunology
-
Psoriasis / therapy
-
Skin Diseases / complications
-
Skin Diseases / diagnosis
Substances
-
Anti-HIV Agents
-
Dermatologic Agents
-
Immunosuppressive Agents